<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="909">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149326</url>
  </required_header>
  <id_info>
    <org_study_id>KN046-303</org_study_id>
    <nct_id>NCT05149326</nct_id>
  </id_info>
  <brief_title>KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Gemcitabine and Nab-Paclitaxel Versus Placebo Combined With Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Ductal Adenocarcinoma Subjects (ENREACH-PDAC-01).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical&#xD;
      efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus&#xD;
      gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who&#xD;
      have not previously received systemic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging</measure>
    <time_frame>up to 1 years</time_frame>
    <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Advanced Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN046</intervention_name>
    <description>KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 3 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18, male or female;&#xD;
&#xD;
          -  Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);&#xD;
&#xD;
          -  Has not received prior systemic treatment for their locally advanced or metastatic&#xD;
             PDAC;&#xD;
&#xD;
          -  Has presence of measurable disease as defined by Response Evaluation Criteria in Solid&#xD;
             Tumours (RECIST 1.1);&#xD;
&#xD;
          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Status;&#xD;
&#xD;
          -  Has a life expectancy of at least 3 months;&#xD;
&#xD;
          -  Has adequate organ function;&#xD;
&#xD;
          -  If female of childbearing potential, have a negative serum pregnancy test within 7&#xD;
             days prior to first trial treatment;&#xD;
&#xD;
          -  If female of childbearing potential or a male subject with a partner with childbearing&#xD;
             potential, be willing to use a highly effective method of contraception (with a&#xD;
             failure rate of less than 1.0% per year) from first study treatment to 24 weeks after&#xD;
             completion of the trial treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated active CNS metastasis or leptomeningeal metastasis.&#xD;
&#xD;
          -  Is currently participating and receiving an investigational drug or has participated&#xD;
             in a study of an investigational drug within 4 weeks or within 5 times of half-life&#xD;
             (no less than 2 weeks), whichever is shorter prior to the first dose of trial&#xD;
             treatment;&#xD;
&#xD;
          -  Has received other anti-tumor treatment within 4 weeks or within 5 times of half-life&#xD;
             (no less than 2 weeks), whichever is shorter prior to the first trial treatment;&#xD;
&#xD;
          -  Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first&#xD;
             administration of trial treatment and/or if the subject has not fully recovered from&#xD;
             the surgery within 4 weeks of the first administration of trial treatment;&#xD;
&#xD;
          -  Curative radiation within 3 months of the first dose of trial treatment. Radiation to&#xD;
             more than 30% of the bone marrow or with a wide field of radiation should not be used&#xD;
             within 4 weeks prior to the first administration of trial treatment;&#xD;
&#xD;
          -  Subjects receiving immunosuppressive agents (such as steroids) for any reason should&#xD;
             be tapered off these drugs before initiation of trial treatment (with the exception of&#xD;
             subjects with adrenal insufficiency, who may continue corticosteroids at physiologic&#xD;
             replacement doses, equivalent to &lt; 10 mg prednisone daily, inhaled steroids and&#xD;
             topical use of steroids);&#xD;
&#xD;
          -  Vaccination within 28 days of the first administration of trial treatment, except for&#xD;
             administration of inactivated vaccines (e.g., inactivated influenza vaccines);&#xD;
&#xD;
          -  Has interstitial lung disease, or a history of pneumonitis that required oral or&#xD;
             intravenous glucocorticoids to assist with management;&#xD;
&#xD;
          -  History or current active autoimmune disease that might deteriorate when receiving an&#xD;
             immunostimulatory agent；&#xD;
&#xD;
          -  Previous malignant disease History of uncontrolled intercurrent illness Prior therapy&#xD;
             with any antibody/drug targeting T cell coregulatory proteins Known severe&#xD;
             hypersensitivity reactions to antibody drug；&#xD;
&#xD;
          -  Is pregnant or breastfeeding;&#xD;
&#xD;
          -  Other medical conditions that at the discretion of investigator interfere with the&#xD;
             requirements of the trial in terms of safety or efficacy evaluation, or treatment&#xD;
             compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

